PDS Biotechnology (PDSB) Common Equity (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Common Equity came in at $9.3 million in Q4 2025, down 51.32% YoY from $19.0 million in Q4 2024, and down 2.13% on a QoQ basis from $9.5 million in Q3 2025.
PDS Biotechnology (PDSB) Common Equity (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Common Equity data on file, last reported at $9.3 million in Q4 2025.
- Quarterly Common Equity fell 51.32% year-over-year to $9.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.3 million (down 51.32% YoY) and the FY2025 annual result came in at $9.3 million, down 51.32% from the prior year.
- Common Equity declined to $9.3 million in Q4 2025, from $9.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $73.0 million in Q2 2021 to a low of $9.3 million in Q4 2025.
- A 5-year average of $35.8 million and a median of $31.7 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity jumped 329.0% — and 2025, when it slumped 57.03%.
- Tracing PDSB's Common Equity over 5 years: stood at $63.2 million in 2021, then tumbled by 30.39% to $44.0 million in 2022, then plunged by 40.61% to $26.1 million in 2023, then declined by 27.27% to $19.0 million in 2024, then sank by 51.32% to $9.3 million in 2025.
- The last three Common Equity figures came in at $9.3 million (Q4 2025), $9.5 million (Q3 2025), and $16.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | PDS Biotechnology | 11.58 Mn | 11.58 Mn | - | -3.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.58 Mn |
| Dec 31, 2025 | 9.25 Mn |
| Sep 30, 2025 | 9.45 Mn |
| Jun 30, 2025 | 15.96 Mn |
| Mar 31, 2025 | 22.36 Mn |
| Dec 31, 2024 | 19.00 Mn |
| Sep 30, 2024 | 22.00 Mn |
| Jun 30, 2024 | 30.92 Mn |
| Mar 31, 2024 | 37.18 Mn |
| Dec 31, 2023 | 26.13 Mn |
| Sep 30, 2023 | 24.48 Mn |
| Jun 30, 2023 | 32.44 Mn |
| Mar 31, 2023 | 41.01 Mn |
| Dec 31, 2022 | 44.00 Mn |
| Sep 30, 2022 | 47.06 Mn |
| Jun 30, 2022 | 51.43 Mn |
| Mar 31, 2022 | 55.87 Mn |
| Dec 31, 2021 | 63.21 Mn |
| Sep 30, 2021 | 67.86 Mn |
| Jun 30, 2021 | 72.99 Mn |